Galapagos: starts phase II trial in lupus

(CercleFinance.com) - On Monday evening Galapagos announced the randomisation of its first patient in GALACELA, a randomised, double-blind, multicenter Phase II trial to evaluate its GLPG3667 in adults with active systemic lupus erythematosus (SLE).


Daily oral administration of GLPG3667 or placebo will be studied in approximately 140 adult SLE patients for 32 weeks. The study will investigate efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics.

SLE is a chronic inflammatory autoimmune disease that affects almost all organ systems, and therefore one of the most heterogeneous diseases treated by physicians, the Belgian biotech company said.


Copyright (c) 2023 CercleFinance.com. All rights reserved.